BioSpace News Archive

Sermonix anticipates dosing the first patient in first half of 2023.

Spectral Medical Inc. announced the opening of two clinical trials sites, the Medical University of South Carolina and the University of California San Francisco, bringing the total number of active clinical trial sites to 16 for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Kamada Ltd. today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023.

REVEAL GENOMICS, S.L. announced a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer.

VBL Therapeutics announced that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem cell-derived, fully differentiated pancreatic islet cell therapy encapsulated into a Vertex-developed, immunoprotective device with the potential to treat type 1 diabetes (T1D).

PerkinElmer Inc. today announced that the Company will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. ET.

Cell One Partners Inc. today announced a strategic partnership to accelerate the development and commercialization of cell and gene therapies.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.

Ansa Biotechnologies, Inc today announced the successful de novo synthesis of the world’s longest DNA oligonucleotide ever reported to be produced in a single synthesis.